Recent research into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are revealing promising results in addressing excess mass and type non-insulin-dependent disease. Animal data suggest a distinct mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/